Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
China Isotope & Radiation Corp. ( (HK:1763) ) just unveiled an update.
China Isotope & Radiation Corporation said its subsidiary Chengdu Gaotong Isotope has agreed to acquire a 51% stake in Hunan Huifeng Engineering Detection, a specialist in non-destructive testing and special equipment inspection. Huifeng Detection brings extensive national qualifications, broad sector coverage from petrochemicals to aerospace and rail, and a large customer base across most regions of China.
Following a 2023 deal for Xi’an Zhanshi Testing & Engineering, the latest acquisition deepens CIRC’s push into non-destructive testing services and will make Huifeng Detection a consolidated controlling subsidiary. The company expects the transaction to strengthen Chengdu Gaotong Isotope’s presence in segmented NDT markets, enhance its comprehensive competitiveness, and further solidify its leading position and influence in China’s special equipment testing industry.
The most recent analyst rating on (HK:1763) stock is a Buy with a HK$26.00 price target. To see the full list of analyst forecasts on China Isotope & Radiation Corp. stock, see the HK:1763 Stock Forecast page.
More about China Isotope & Radiation Corp.
China Isotope & Radiation Corporation is a PRC-based joint stock company focused on radioactive sources and application technologies, operating through subsidiaries such as Chengdu Gaotong Isotope. The group targets a full-chain ecosystem from radioactive sources to equipment and back-end services, and holds a dominant share in China’s non-destructive testing radioactive source market.
Average Trading Volume: 193,955
Technical Sentiment Signal: Buy
Current Market Cap: HK$6.97B
See more insights into 1763 stock on TipRanks’ Stock Analysis page.